

Correction

Correction: Guerrieri et al. Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection. *Vaccines* 2021, 9, 1499

Mariapia Guerrieri ^{1,†}, Beatrice Francavilla ^{1,*,†} , Denise Fiorelli ², Marzia Nuccetelli ², Francesco Maria Passali ¹, Luca Coppeta ³ , Giuseppina Somma ³, Sergio Bernardini ^{2,4}, Andrea Magrini ³ and Stefano Di Girolamo ¹

¹ Department of Otorhinolaryngology, University of Rome “Tor Vergata”, 00100 Rome, Italy

² Department of Experimental Medicine, University of Rome “Tor Vergata”, 00100 Rome, Italy

³ Department of Occupational Medicine, University of Rome “Tor Vergata”, 00100 Rome, Italy

⁴ Department of Laboratory Medicine, Tor Vergata University Hospital, 00100 Rome, Italy

* Correspondence: beatrice.francavilla@ptvonline.it

† These authors contributed equally to this work.

Error in Figure

The authors wish to make the following corrections to this paper [1]:

In the original publication, there was a mistake in Figure 2 as published. The same image was mistakenly selected for Figure 2 and Figure 3 during proofreading. The corrected Figure 2 appears below.



Citation: Guerrieri, M.; Francavilla, B.; Fiorelli, D.; Nuccetelli, M.; Passali, F.M.; Coppeta, L.; Somma, G.; Bernardini, S.; Magrini, A.; Di Girolamo, S. Correction: Guerrieri et al. Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection. *Vaccines* 2021, 9, 1499. *Vaccines* 2023, 11, 172. <https://doi.org/10.3390/vaccines11010172>

Received: 12 December 2022

Accepted: 3 January 2023

Published: 13 January 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).




Figure 2. Anti-SARS-CoV-2 IgA-S1 and anti-SARS-CoV-2 IgG-RBD in saliva samples. (a) Saliva sample median levels of anti-SARS-CoV-2 IgA-S1 in the three study groups, expressed as COI (Cut off index). (b) Saliva sample median levels of anti-SARS-CoV-2 IgG-RBD in the three study groups, expressed as Binding Antibody Units (BAU/mL). In the COVID-19 group, the red rhombuses represent the hospitalized subjects. Statistical analysis and construction of figures were performed with GraphPad Prism 8 Software (GraphPad Software, San Diego, CA, USA). The D’Agostino and Pearson test, the Shapiro-Wilk normality test, and the Kolmogorov–Smirnov test were used to evaluate non-Gaussian distributions in all of the study populations. The continuous data were displayed as median and range. Non-parametric results were analysed with the Mann–Whitney test. For all results, $p < 0.05$ was considered statistically significant.

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

1. Guerrieri, M.; Francavilla, B.; Fiorelli, D.; Nuccetelli, M.; Passali, F.M.; Coppeta, L.; Somma, G.; Bernardini, S.; Magrini, A.; Di Girolamo, S. Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection. *Vaccines* **2021**, *9*, 1499. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.